Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioceres Crop Solutions (BIOX) Net Income towards Common Stockholders (2016 - 2026)

Bioceres Crop Solutions' Net Income towards Common Stockholders history spans 5 years, with the latest figure at -$9.0 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 446.15% to -$9.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$6.4 million, a 7.38% decrease, with the full-year FY2025 number at -$55.4 million, down 1396.07% from a year prior.
  • Net Income towards Common Stockholders hit -$9.0 million in Q1 2026 for Bioceres Crop Solutions, down from $2.6 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for BIOX hit a ceiling of $2.6 million in Q1 2025 and a floor of -$9.0 million in Q1 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$5.0 million across 3 years, with a median of -$8.6 million in 2022.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 182.04% in 2022 and later plummeted 446.15% in 2026.
  • Tracing BIOX's Net Income towards Common Stockholders over 3 years: stood at -$8.6 million in 2022, then skyrocketed by 130.37% to $2.6 million in 2025, then plummeted by 446.15% to -$9.0 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for BIOX at -$9.0 million in Q1 2026, $2.6 million in Q1 2025, and -$8.6 million in Q2 2022.